{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+matched", "query": { "intervention": "Placebo- matched" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 6947, "total_pages": 695, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+matched&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-17T21:01:49.111Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03633227", "title": "Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Liver Cirrhosis, Biliary" ], "interventions": [ { "name": "Obeticholic Acid (OCA)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intercept Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 22, "start_date": "2018-06-22", "completion_date": "2021-07-09", "has_results": true, "last_update_posted_date": "2022-09-06", "last_synced_at": "2026-09-17T21:01:49.111Z", "location_count": 11, "location_summary": "Rialto, California • Sacramento, California • Miami, Florida + 8 more", "locations": [ { "city": "Rialto", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03633227" }, { "nct_id": "NCT01514461", "title": "A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Familial Chylomicronemia Syndrome (FCS)" ], "interventions": [ { "name": "LCQ908", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2012-07", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2015-06-03", "last_synced_at": "2026-09-17T21:01:49.111Z", "location_count": 1, "location_summary": "Seatlle, Washington", "locations": [ { "city": "Seatlle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01514461" }, { "nct_id": "NCT07290283", "title": "A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "AZD3974", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 176, "start_date": "2025-12-10", "completion_date": "2026-10-21", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-09-17T21:01:49.111Z", "location_count": 2, "location_summary": "Glendale, California • Baltimore, Maryland", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07290283" }, { "nct_id": "NCT03941483", "title": "Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury (AKI) Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Kidney Injury (AKI)" ], "interventions": [ { "name": "ASP1128", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": null, "sex": "ALL", "summary": "35 Years and older" }, "enrollment_count": 351, "start_date": "2019-11-01", "completion_date": "2021-10-20", "has_results": true, "last_update_posted_date": "2024-12-04", "last_synced_at": "2026-09-17T21:01:49.111Z", "location_count": 27, "location_summary": "Huntsville, Alabama • Tucson, Arizona • Clearwater, Florida + 23 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03941483" }, { "nct_id": "NCT03764618", "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Warm Antibody Autoimmune Hemolytic Anemia" ], "interventions": [ { "name": "Fostamatinib disodium", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rigel Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 90, "start_date": "2019-04-24", "completion_date": "2022-04-11", "has_results": true, "last_update_posted_date": "2023-05-25", "last_synced_at": "2026-09-17T21:01:49.111Z", "location_count": 26, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 22 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03764618" }, { "nct_id": "NCT00842088", "title": "Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "HQK-1001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HemaQuest Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "12 Years to 60 Years" }, "enrollment_count": 24, "start_date": "2009-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2011-08-01", "last_synced_at": "2026-09-17T21:01:49.111Z", "location_count": 8, "location_summary": "Madison, Alabama • Oakland, California • Daytona Beach, Florida + 5 more", "locations": [ { "city": "Madison", "state": "Alabama" }, { "city": "Oakland", "state": "California" }, { "city": "Daytona Beach", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00842088" }, { "nct_id": "NCT05123703", "title": "A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing-remitting Multiple Sclerosis" ], "interventions": [ { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Ocrelizumab Placebo", "type": "OTHER" }, { "name": "Fingolimod", "type": "DRUG" }, { "name": "Fingolimod Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "10 Years to 17 Years" }, "enrollment_count": 188, "start_date": "2022-05-19", "completion_date": "2029-09-17", "has_results": true, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-09-17T21:01:49.111Z", "location_count": 10, "location_summary": "La Jolla, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05123703" }, { "nct_id": "NCT02484703", "title": "A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of Age", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Down Syndrome" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "RO5186582", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "6 Years to 11 Years" }, "enrollment_count": 45, "start_date": "2015-10-28", "completion_date": "2016-08-03", "has_results": false, "last_update_posted_date": "2017-07-06", "last_synced_at": "2026-09-17T21:01:49.111Z", "location_count": 9, "location_summary": "Phoenix, Arizona • Decatur, Georgia • Chicago, Illinois + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02484703" }, { "nct_id": "NCT02697773", "title": "Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Osteoarthritis, Knee", "Osteoarthritis, Hip" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "Tanezumab 2.5 mg", "type": "BIOLOGICAL" }, { "name": "Tanezumab 2.5mg/5mg", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 698, "start_date": "2016-01-21", "completion_date": "2018-05-14", "has_results": true, "last_update_posted_date": "2021-05-03", "last_synced_at": "2026-09-17T21:01:49.111Z", "location_count": 68, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Surprise, Arizona + 54 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Surprise", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02697773" }, { "nct_id": "NCT04594369", "title": "A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Cystic Fibrosis Bronchiectasis" ], "interventions": [ { "name": "Brensocatib 10 mg", "type": "DRUG" }, { "name": "Brensocatib 25 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Insmed Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "12 Years to 85 Years" }, "enrollment_count": 1767, "start_date": "2020-12-01", "completion_date": "2024-10-28", "has_results": true, "last_update_posted_date": "2025-12-16", "last_synced_at": "2026-09-17T21:01:49.111Z", "location_count": 67, "location_summary": "Birmingham, Alabama • Conway, Arkansas • Little Rock, Arkansas + 61 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Conway", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04594369" } ] }